United Therapeutics (UTHR) Cash from Financing Activities (2009 - 2026)

United Therapeutics has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$1.5 billion for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1.5 billion, down 1482.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 billion (down 805.42% YoY), and the FY2025 annual result was -$1.2 billion, up 8.35% from the prior year.
• Cash from Financing Activities came in at -$1.5 billion for Q1 2026 at United Therapeutics, down from $98.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $98.4 million in Q4 2025 to a low of -$1.5 billion in Q1 2026.
• The 5-year median for Cash from Financing Activities is -$48.0 million (2024), against an average of -$225.0 million.
• Across the five-year window, Cash from Financing Activities soared 640.0% in 2022 and tumbled 2297.53% in 2024, its largest moves.
• United Therapeutics' Cash from Financing Activities stood at $55.5 million in 2022, then sank by 267.21% to -$92.8 million in 2023, then increased by 19.5% to -$74.7 million in 2024, then soared by 231.73% to $98.4 million in 2025, then tumbled by 1608.54% to -$1.5 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$1.5 billion (Q1 2026), $98.4 million (Q4 2025), and -$956.0 million (Q3 2025), per Business Quant data.